Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPSC-Derived CD8 αβ T Cells
- Development stage
- Unknown
- Lead developer
- Agency for Medical Research and Development
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Portal Vein
01
Overview
iPSC-Derived CD8 αβ T Cells are an adoptive cell therapy derived from inducible pluripotent stem cells (iPSCs). These engineered CD8αβ T cells express a T-cell receptor (TCR) specifically targeting HLA-A24-restricted GPC3 peptides, enabling TCR-dependent killing of tumor cells. Additionally, they are designed for innate, TCR-independent killing through markers like NKG2D and DNAM1. The cells are armored with constitutive IL-15/IL-21 secretion to enhance acute and serial killing activity and include immune evasion edits to prevent cellular and humoral rejection, aiming for enhanced persistence in the tumor microenvironment. This therapy is being developed to address challenges in solid tumors, such as target antigen downregulation and cell trafficking.
02
Targets
GPC3 (Glypican-3)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL21R (Interleukin-21 receptor)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on iPSC-Derived CD8 αβ T Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPSC-Derived CD8 αβ T Cells.